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Abstract
Human immunodeficiency virus type 1 (HIV-1) genomes often carry one or more mutations associated with drug resistance
upon transmission into a therapy-naı ¨ve individual. We assessed the prevalence and clinical significance of transmitted drug
resistance (TDR) in chronically-infected therapy-naı ¨ve patients enrolled in a multi-center cohort in North America. Pre-
therapy clinical significance was quantified by plasma viral load (pVL) and CD4+ cell count (CD4) at baseline. Naı ¨ve bulk
sequences of HIV-1 protease and reverse transcriptase (RT) were screened for resistance mutations as defined by the World
Health Organization surveillance list. The overall prevalence of TDR was 14.2%. We used a Bayesian network to identify co-
transmission of TDR mutations in clusters associated with specific drugs or drug classes. Aggregate effects of mutations by
drug class were estimated by fitting linear models of pVL and CD4 on weighted sums over TDR mutations according to the
Stanford HIV Database algorithm. Transmitted resistance to both classes of reverse transcriptase inhibitors was significantly
associated with lower CD4, but had opposing effects on pVL. In contrast, position-specific analyses of TDR mutations
revealed substantial effects on CD4 and pVL at several residue positions that were being masked in the aggregate analyses,
and significant interaction effects as well. Residue positions in RT with predominant effects on CD4 or pVL (D67 and M184)
were re-evaluated in causal models using an inverse probability-weighting scheme to address the problem of confounding
by other mutations and demographic or risk factors. We found that causal effect estimates of mutations M184V/I
({1:7log10 pVL) and D67N/G ({2:1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
and z0:4log10 pVL) were compensated by K103N/S and K219Q/E/N/R. As TDR
becomes an increasing dilemma in this modern era of highly-active antiretroviral therapy, these results have immediate
significance for the clinical management of HIV-1 infections and our understanding of the ongoing adaptation of HIV-1 to
human populations.
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Introduction
A substantial fraction (&5%–20%) of human immunodeficiency
virus type 1 (HIV-1) variants that are transmitted and establish
infections in individuals who have never been exposed to
antiretroviral drugs (i.e., ARV-naı ¨ve) already carry one or more
mutations that are associated with resistance to ARVs [1,2].
Resistance mutations are generally slow to revert in ARV-naı ¨ve
hosts [3,4] and can persist at low frequencies in treatment-
experienced hosts as well [5]. The pre-existence of resistance
mutations can significantly diminish effectiveness of subsequent
ARV therapy [6,7]; for example, transmitted K103N mutations are
associated with increased regimen failure and poorer outcomes on
non-nucleoside reverse transcriptase inhibitors (NNRTIs) [8]. On
the other hand, resistance mutations can also incur a measurable
cost with respect to virus replicative capacity in vitro [9–11] and
competitive growth in vivo [12]. Within therapy-naı ¨ve hosts, the
fitness costs of transmitted drug resistance (TDR) mutations may
influence the subsequent evolution and population dynamics of
HIV-1. With the exception of limiting the choice of initial ARV
regimens, however, the direct clinical consequences of TDR
mutations in therapy-naı ¨ve hosts remain inconclusive [13–17].
Our central hypothesis in this study is that the presence of TDR
mutations in therapy-naı ¨ve hosts has a measurable effect on not
only the subsequent rate of growth of the virus population within
the host, but also on the rate of depletion of CD4+ T-lymphocytes
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21189that are targeted by HIV-1. To evaluate this hypothesis, we assess
the relationship between TDR mutations and prognostic clinical
markers – CD4+ T-cell count (CD4) and plasma HIV-1 RNA load
(pVL) – at baseline using data from the Centers for AIDS
Research (CFAR) Network of Integrated Clinical Systems
(CNICS), an observational cohort created from a data-sharing
collaboration between multiple clinical sites in North America
[18]. ‘Baseline’ refers to the measurements of clinical markers
upon HIV diagnosis and/or entry into clinical care. It does not
correspond to a consistent time point after infection and many
patients will have already progressed into the chronic phase of
infection. Nevertheless, these data can provide useful insight into
the clinical implications of TDR in therapy-naı ¨ve hosts.
First, we quantify the effects of TDR mutations at both
aggregate and position-specific levels. An aggregate approach
sums across mutations occupying different positions in HIV-1
protease and reverse transcriptase, implicitly assuming that every
mutation has a similar effect (in both direction and magnitude) on
baseline CD4 or pVL. In contrast, a position-specific analysis
recognizes the possibility that some TDR mutations will have a
disproportionately large effects while others have negligible effects.
Furthermore, it enables us to identify compensatory interactions,
such that the effect of a specific mutation on CD4 or pVL depends
on the presence or absence of other mutations; such interactions
are an important aspect of the evolution of drug resistance in HIV-
1 [11]. Second, we re-evaluate statistically significant associations
of individual TDR mutations in a causal modeling framework, i.e.,
inverse probability-of-treatment weighting [19]. A statistical
association between a treatment (a TDR mutation) and an
outcome (baseline CD4 or pVL) in an observational study may be
biased if one or more variables, such as other co-transmitted
resistance mutations, are not only correlated with the treatment
but also affect the outcome [19]. In the presence of such
confounding factors, the significant association could be wrongly
attributed to a causal effect of the treatment on the outcome.
Using statistical procedures that can adjust for confounding by
weighting observational data has become an important compo-
nent of understanding the consequences of drug resistance in HIV
[20].
Methods
Ethics statement
All patients in the CNICS database have provided informed
written consent, as reviewed and approved by the institutional
review boards of all participating sites – University of Alabama,
Birmingham (UAB); University of California, San Diego (UCSD);
University of California, San Francisco (UCSF); University of
Washington (UW); Case Western Reserve University (CWRU);
and Harvard University (FENWAY) – to have their clinical
information used for the purposes of research. Patients were
informed on the minimum information being collected, alterna-
tives to participation, and possible uses of the data. In addition,
CNICS has received a Certificate of Confidentiality from the
National Institutes of Health (NIH).
Data collection
The study population comprised individuals from 6 CNICS
sites: University of Alabama, Birmingham; University of Califor-
nia, San Diego; University of California, San Francisco; University
of Washington; Case Western Reserve University; and Harvard
University [18]. All patients in the CNICS database have provided
informed written consent, as reviewed and approved by the
institutional review boards of all participating sites, to have their
clinical information used for the purposes of research. HIV-1 pol
sequences in the region encoding protease and/or part of reverse
transcriptase (i.e., the first 246–400 codons of RT) were obtained at
each site by conventional Sanger sequencing directly from RT-
PCR amplification products from sample extractions of viral
RNA. The exact bulk sequencing protocol varied among sites, as
some sites used commercial laboratory services (viz., Monogram,
Quest, Virco, LabCorp) whereas others used in-house assays based
on commercial kits. At the time of this study, 4914 codon or amino
acid sequences were available in the CNICS database but many
were obtained when patients were on-therapy. Amino acid
sequences were reconstituted from reports of residue polymor-
phisms relative to the HXB2 reference sequence. Sequences were
linked to: unique anonymized patient identifiers; CNICS site;
sampling date; age; ARV regimens; demographic factors (self-
reported gender at baseline, race/ethnicity); HIV risk factors (men
who have sex with men, MSM; injection drug use, IDU); baseline
plasma HIV RNA titres (pVL, virus/mL plasma); and baseline
CD4 cell counts (cells/mL). A patient record was included in this
study if: (1) a sequence was sampled before therapy, and (2) CD4
and/or pVL were sampled within 120 days of the sequence sample
date. To normalize the distributions of pVL and CD4, we used
log10 and cube-root transformations [21], respectively. Race and
ethnicity records were aggregated into the following groups: non-
Hispanic white, non-Hispanic black, Hispanic, and other. Non-
random associations between demographic and risk factors were
identified using log-linear models.
Sequence analysis
Sequences were aligned pairwise against the NL4-3 pol reference
sequence using an implementation of the Gotoh algorithm in
HyPhy [22,23] under default settings. Surveillance drug resistance
mutations (SDRMs) were tallied for each amino acid sequence
according to the 2009 update of the World Health Organization
list of surveillance drug resistance mutations (SDRMs) [24]. Amino
acid polymorphisms (e.g., bulk sequence mixtures) were resolved to
the resistant residue when applicable.
Statistical analysis
Resistance scores by drug class (protease inhibitors, PIs;
nucleoside and non-nucleoside reverse transcriptase inhibitors,
NRTIs/NNRTIs) were calculated according to the Stanford HIV
Drug Resistance database algorithm [25]. The Stanford scoring
system is a linear predictor of drug resistance phenotypes that
works by assigning integer weights to a sequence for encoding
resistance-associated amino acid residues at specific positions.
Weights (or ‘scores’) for a given sequences were calculated for
every drug in a given drug class. We used the highest score of any
drug in a drug class as the class-specific score. These quantitative
scores, denoted by SPI, SNRTI and SNNRTI respectively, were used
to analyze the aggregate effects of TDR on baseline CD4 and
pVL. Aggregate or position-specific effects of TDR on baseline
CD4 or pVL were evaluated alongside demographic and risk
factors in linear models. In each case we used a bi-directional
stepwise algorithm in R (stepAIC [26]) to select a ‘best-fitting’ linear
model based on the Akaike information criterion (AIC), which
penalizes model likelihood by the number of parameters. We
seeded the algorithm with the full additive model (without
interaction terms) and limited model complexity to second-order
interactions. To avoid over-fitting the data from evaluating a large
number of alternative models, we averaged parameter estimates
and P values over an ensemble of models (best +5 next-best) using
Akaike weights [27].
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probability-of-treatment weight (IPTW) estimators [19]. The
conditional probability Pr(AjL) for a given ‘treatment’ variable
(A) was computed by fitting a logistic model of A against the set of
all potential confounding variables (L). To account for compen-
satory interactions among mutations, we combined the corre-
sponding presence/absence variables into a single multinomial
treatment as suggested to us by Miguel A. Herna ´n (pers. comm.).
For example:
AM184~
0 if M184X~0 and (K103X~0 and K219X~0)
1 if M184X~1 and (K103X~0 and K219X~0)
2 if M184X~1 and (K103X~1 or K219X~1)
8
> <
> :
where X signifies any SDRM residue at that position. Conditional
probabilities for multinomial treatments were obtained by fitting a
multinomial logistic model with the multinom function in the R
package nnet. Because weighting observations by the inverse of
Pr(AjL) can introduce excessive variability, we used stabilized
weights that normalize Pr(AjL) by the marginal probability
Pr(A), which was estimated by fitting a logistic model containing
only the intercept term [19]. The stabilized weights were
incorporated into a linear model of baseline CD4 or pVL on
treatment A using the svyglm function in the R package survey [28],
which uses an estimating equation-based approach to fitting
generalized linear models with robust standard errors. Cases with
missing data were omitted from these analyses.
A Bayesian network analysis to detect co-transmission of TDR
mutations was carried out using a Markov chain Monte Carlo
(MCMC) procedure in HyPhy [29]. A Bayesian network is a
compact representation of the joint probability distribution of
multiple variables (i.e., the presence/absence of TDR mutations),
where ‘joint’ implies that the probability distribution of a variable
may be conditional on other variables in the network [30]. In
other words , a Bayesian network provides an efficient framework
for exploring the statistical interactions among variables. Each
variable is represented by a ‘node’ in the network, and connections
between nodes (‘edges’) are drawn to indicate that one variable is
conditioned on the second. The MCMC procedure obtains a
random sample of Bayesian networks from the posterior
probability distribution defined by the data. The Markov chain
was propagated for 106 steps, discarding the first half as burn-in
and thinning the remaining sample to 100 steps at equal intervals.
Edges in the network signifying co-transmission were accepted if
they were present in 90% or more of the networks in the sample.
Results
Population
The study population was comprised of 14111 individuals with
a median baseline CD4 of 300 cells/mL (n~14011) and a median
baseline pVL of 24400 copies/mL (n~13953). Median year of
birth was 1964. The majority of the population self-reported as
‘white’ (n~8694). 3725 individuals self-reported as ‘black’, 207 as
‘Asian/Pacific Islander’ and 835 as ‘other’; there were 650 non-
respondents. At the time of this study, the CNICS database
contained 1585 sequence records that we classified as therapy-
naı ¨ve. Out of these, 1575 naı ¨ve sequences were linked to baseline
CD4 and pVL records. 1526 naı ¨ve sequences were associated with
baseline CD4 records within 120 days of the sequence sampling
date and were otherwise censored from subsequent analyses.
Likewise, 1516 naı ¨ve sequences were associated with baseline pVL
within 120 days of sampling and were otherwise censored. The
median baseline CD4 and pVL of patients with naı ¨ve sequences in
this data set were 285 cells/mL and 104:7 copies/mL, respectively.
Composition of the naı ¨ve sample with respect to race was
significantly associated with gender (x2~68:2, df~3,
P~1:03|10{14); e.g., the sample included a disproportionately
greater number of naı ¨ve sequences from white males (odds ratio,
OR~3:1) and black females (OR~3:0). Sample composition by
race was also significantly associated with MSM (x2~138:8,
df~3, P~7:05|10{30), largely because of a greater number of
white MSMs than expected by marginal frequencies (OR~2:85).
Prevalence of transmitted SDRMs
Overall, 225 out of 1585 naı ¨ve sequences (14.2%) contained one
or more SDRMs. Of these 225 sequences, 66 (4.2%) contained at
least one PI-associated SDRM, 130 (8.2%) contained at least one
NRTI-associated SDRM, and 131 (8.3%) contained at least one
NNRTI-associated SDRM. In addition, 17 (1.1%) sequences
contained SDRMs in all three drug classes, which is substantially
greater than the number expected by chance (v0:5 sequences) if
the joint transmission of mutations was independent of drug class.
A decline from pre-2003 levels in the fraction of naı ¨ve sequences
with at least 1 SDRM was mirrored by a similar decline in the
mean number of SDRMs per naı ¨ve sequence (Figure 1). However,
we observed an increase in the most recent sample year (2008) in
the upper 95% quartile of the distribution in the number of
SDRMs. Neither measure of prevalence was significantly associ-
ated with demographic or risk factors in generalized linear models
(Pw0:05). Counts of SDRMs by residue position are provided in
Table 1. A Bayesian network analysis detected significant co-
transmission of SDRMs in four groups (Figure 2). The largest
group generally corresponded to NRTI resistance-associated
Figure 1. Prevalence of transmitted surveillance drug resis-
tance mutations (SDRMs) over time. Sampling years 1998–2002
were grouped into a single level (‘pre-2003’) to adjust for small sample
sizes (n~3,5,18, and 56, respectively). Sample sizes for the bins are
displayed below the x-axis. Dashes (2) indicate the fraction of naı ¨ve
sequences in a given sampling period that contain at least one SDRM
(right y-axis). The trend in mean number of SDRMs per naı ¨ve sequence
(left y-axis) over time is displayed as a solid line annotated with the
actual values. The 95% quantile per time point is depicted by a lighter
line bounding a shaded region to illustrate the trend in the distributions
(all medians were zero).
doi:10.1371/journal.pone.0021189.g001
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contained well-characterized mutational pathways, e.g., D67/
T69/K70/K219 and T215/M41/L210. Two smaller groups
(M46/I84/I85 and D30/N88) comprised mutations associated
with PI resistance, the latter group being associated with resistance
to nelfinavir in particular. The remaining group (K101/G190)
comprised mutations associated with resistance to NNRTIs. In
sum, co-transmitted SDRMs tended to confer resistance to the
same drug or drug class.
Aggregate SDRM predictors of baseline CD4 and HIV
RNA
The summated Stanford scores for NRTI and NNRTI (SNRTI,
SNNRTI) and race/ethnicity were significantly (a~0:05) associated
with baseline CD4 (Table 2). For every 10 units of SNRTI and
SNNRTI, the model predicted a decline in
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
by about 0:07
and 0:04 units, respectively. For example, if a hypothetical patient
whose CD4 count matched the study median (285 cells/mL)
became infected by an HIV-1 variant carrying SDRMs such that
SNRTI~100 and SNNRTI~100, we would predict a baseline CD4
count of (
ﬃﬃﬃﬃﬃﬃﬃﬃ
285
3 p
{0:069|10{0:044|10)
3&162 cells/mL. The
joint effect of transmitted RTI resistance on CD4 is illustrated in
Figure 3. Only about 5:8% of the variance in
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
was
explained by this model. Similarly, SNRTI, SNNRTI, gender and
race/ethnicity were significantly associated with baseline pVL
(Table 2). For every 10 units in SNRTI, pVL was predicted to
decline by about 0:03log10 units; in contrast, pVL was predicted
to increase by about 0:02log10 units for every 10 units in SNNRTI
(Figure 4). Only 2% of the variance in log10 pVL was explained by
this model. SPI was not significantly associated with either CD4 or
pVL at baseline.
Position-specific SDRM predictors of baseline CD4 and
HIV RNA
Although aggregate SDRM-based statistics such as Stanford
scores are convenient and easy to interpret as proximate measures
of drug class-specific resistance, they may mask the effects of
individual mutations on clinical outcome. Consequently, we
assessed the effects of position-specific SDRMs in linear models
of baseline CD4 and pVL. To minimize the number of predictor
variables and avoid over-fitting of the data, we limited our analysis
to positions with a minimum SDRM frequency of 1% in naı ¨ve
sequences (see Table 1). These positions were: M46, I54, and L90
in protease, and; M41, D67, M184, L210, T215, K219, K103,
Y181, and G190 in reverse transcriptase. The presence or absence
of SDRMs at each position was represented by a binary variable
(herein denoted by appending an ‘X’ to the amino acid positional
notation, e.g., M46X={0,1}).
D67X and K219X were each associated with significantly lower
baseline CD4 (Pv0:04; Table 3); both sets of SDRMs are
thymidine analog mutations (TAMs) conferring resistance to
NRTIs. For example, the model would predict a hypothetical
decline from 400 cells/mL to 146 and 235 cells/mL with the
introduction of SDRMs at positions D67 and K219, respectively.
In addition, there was a significant interaction effect between
D67X and K219X associated with a compensatory increase by
Table 1. Number and percentage prevalence of putatively transmitted surveillance drug resistance mutations (SDRMs) by residue
position in antiretroviral (ARV)-naı ¨ve sequences.
Class position count % prevalence Class position count % prevalence
PI L23 1 0.06 NRTI(cont’d) K70 9 0.57
L24 1 0.06 L74 11 0.69
D30 15 0.95 V75 2 0.13
V32 2 0.13 F77 1 0.06
M46 20 1.26 Y115 1 0.06
I47 2 0.13 F116 1 0.06
G48 0 0 Q151 0 0
I50 2 0.13 M184 40 2.52
F53 1 0.06 L210 29 1.83
I54 16 1.01 T215 77 4.86
G73 3 0.19 K219 30 1.89
L76 1 0.06 NNRTI L100 1 0.06
V82 12 0.76 K101 7 0.44
N83 0 0 K103 82 5.17
I84 10 0.63 V106 2 0.13
I85 2 0.13 V179 1 0.06
N88 15 0.95 Y181 24 1.51
L90 30 1.89 Y188 10 0.63
NRTI M41 49 3.09 G190 24 1.51
K65 3 0.19 P225 1 0.06
D67 28 1.77 M230 0 0
T69 9 0.57
PI=protease inhibitor; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0021189.t001
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ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
(P~0:006; Figure 5). This model
accounted for 6.8% of the variance in
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
.
M184X was significantly associated with an approximately ten-
fold lower pVL at baseline (P~1:3|10{7; Table 3). M46X and
L210X were also significantly associated with lower baseline pVL
(Pv0:01) and D67X was associated with greater pVL (P~0:009).
We also observed several significant mutational interaction terms
in the model. For instance, interactions between M184X and
either K103X or K219X were associated with a compensatory
increase in pVL (P~0:018 and P~0:023, respectively; Figure 5).
Similarly, a decline in pVL associated with M46X was
compensated by T215X (P~0:033). An interaction term between
D67 and K219, which was encountered in the preceding model on
CD4, was also statistically significant in this model of pVL
Figure 2. Bayesian network depicting conditional dependen-
cies among surveillance drug resistance mutations (SDRMs) in
ARV-naı ¨ve sequences. Each labeled node corresponds to a position
in protease [rectangular] or RT (rounded). Nodes without dependencies
(L23, L24, V32, I47, I50, F53, G73, L76, K65, V75, F77, Y115, F116, L100,
V106, V179, Y181, and Y188) were omitted from the graph for clarity.
Connections between nodes (edges) are labeled with the log10 odds
ratio of the 2|2 contingency table for the presence/absence of SDRMs
at the respective sites, e.g., an SDRM at position PR-D30 is estimated to
be 103:6&4000 times more likely to be present in an ARV-naı ¨ve
sequence that contains an SDRM at position PR-N88. Line widths for
e d g e sa r ea l s od r a w ni np r o p o r t i o nt ot h el o g 10 odds ratios.
Inf=infinity, i.e., unable to estimate because of zero count(s) in the
contingency table.
doi:10.1371/journal.pone.0021189.g002
Figure 3. CD4 cell count (raw) plotted against the sum of
Stanford scores for nucleoside and non-nucleoside reverse
transcriptase inhibitors (SNRTI and SNNRTI, respectively). The
upper limit of CD4 (2073 cells/mL) was truncated to 1000 cells/mL
(omitting 19 outliers) to emphasize the overall trend. Because the
predicted baseline CD4 tended to decline with both SNRTI and SNNRTI,
we combined the scores into a single ordinal variable to facilitate
interpretation. The linear model prediction is displayed as a solid line
(generated by fitting a smoothing spline to the predicted values with
smoothing parameter a~0:9), with 95% confidence intervals displayed
as dashed lines.
doi:10.1371/journal.pone.0021189.g003
Table 2. Coefficient estimates from Akaike Information Criterion (AIC)-selected linear models of baseline
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
and plasma HIV
RNA on Stanford scores by drug class and demographic and risk factors.
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
log10 plasma HIV RNA
Estimate (95% CI) P value Estimate (95% CI) P value
SNRTI {6:9 ({12:2, {1:1)|10{3 0.02 {3:2 ({0:8, {5:7)|10{3 0.009
SNNRTI {4:4 ({8:4, {0:5)|10{3 0.035 1.7 (0.04, 3.4)|10{3 0.045
Male NS 0.19 (0.06, 0.32) 0.006
Race/ethnicity
Black {0:35 ({0:61, {0:09) 0:008 {0:15 ({0:26,0:04) 0.007
Hispanic {0:57 ({0:86, {0:28) 1:1|10{4 NS
All estimates were averaged over an ensemble of linear models using Akaike weights. Only statistically significant (a~0:05) terms after weighting are reported. Linear
effects of factors were estimated relative to the model intercept, i.e., a hypothetical female white individual. NS=not significant.
doi:10.1371/journal.pone.0021189.t002
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D67X on pVL by about 0.6 log10 units. Approximately 6.7% of
variation in pVL was explained in this model, over three times as
much as the aggregate model.
Causal inference
We used an inverse probability weighting scheme (using
stabilized weights) to disentangle the causal effects of SDRMs
from confounding variables that influence both the probability of
the ‘treatment’ (an SDRM at the position in question) and CD4 or
pVL. Based on the results of the preceding section, we focussed on
the compensated and uncompensated effects of M184X on
baseline pVL, and of D67X on both pVL and
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
. K103X
and K219X were assumed to be interchangeable with respect to
their compensatory interactions with M184X. Consequently, the
multinomial outcome AM184 comprised n~1445, 19 and 15 cases
for the respective levels 0, 1 and 2 (i.e., wildtype, uncompensated
M184X, and M184X compensated by K103X and/or K219X). In
an unweighted univariate linear model, M184X was significantly
associated with a {1:1 decline in log10 pVL in the absence of
K103X and/or K219X (Table 4). Stabilized weights adjusting for
the conditional probability of carrying M184X ranged from 0.02
to 18.72 with a mean of 1.016. Adding stabilized weights to the
model exposed a greater deleterious effect of M184X on log10
pVL ({1:69 units) when uncompensated by K103X and/or
K219X. Similarly, re-weighting linear models resulted in larger
estimated effects of uncompensated D67X on both baseline CD4
({2.1 units
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
) and pVL (2.5-fold increase; Table 4).
Stabilized weights adjusting for the conditional probability of
carrying D67X ranged from 0.006 to 12.3 with a mean of 1.003.
For both pVL and CD4, the effects of D67X compensated by
K219X became statistically significant and reversed sign relative to
the unadjusted models (Table 4).
Discussion
The overall prevalence of transmitted drug resistance (TDR)
mutations in therapy-naı ¨ve patients has been reported in a large
number of study populations around the world and ranges from 0
to 25% [1]. On the other hand, the transmission of a specific
mutation is a relatively infrequent event whose prevalence requires
very large samples (over 1000 individuals) to estimate. This
requirement has generally been achieved by integrating study
populations from similar geographic regions, such as the
Combined Analysis of Resistance Transmission over Time of
Chronically and Acute Infected HIV Patients (CATCH) study
encompassing 27 countries in Europe [31], the Swiss HIV Cohort
Study [32], the UK Collaborative HIV cohort study [14], and the
Centers for AIDS Research (CFAR) Network of Integrated
Clinical Systems (CNICS) cohort reported in this study. Here we
briefly compare and contrast the prevalence of drug class-specific
and site-specific TDR across these integrated cohorts. First,
NRTI-associated SDRMs generally tend to be more prevalent
than SDRMs associated with PIs or NNRTIs. Our sample
deviates slightly from this trend in that the prevalence of naı ¨ve
sequences with §1 NNRTI-associated SDRM is similar to
sequences with §1 NRTI-associated SDRM, largely due to an
atypically high frequency of transmitted mutations at RT-K103
(5.2%) in our sample. Second, SDRMs that are slow to revert in
the absence of selection (e.g., M41L, K103N, and T215X in RT
and L90M in protease), implying a negligible cost to fitness [1],
tend to have relatively high prevalence in therapy-naı ¨ve sequences.
The foremost and best -documented clinical implication of
TDR is that it impedes the virological response to subsequent drug
therapy [6–8]. In contrast, the clinical implications of TDR in the
absence of drug therapy are subtle and less well understood. These
effects have been difficult to elucidate because the transmission of
SDRMs remains an infrequent event at the scale of individual
mutations. Investigators have attempted to overcome the limita-
tions of insufficient sample sizes by evaluating the effects of
aggregate statistics of TDR, such as an ‘all-or-none’ statistic that
groups sequences carrying one or more SDRMs [14,16,17]. While
this approach is convenient and easy to interpret, it is subject to
confounding because different drug classes or mutations can have
opposite effects on prognostic clinical markers. Our use of a large
data set from a multi-center cohort enabled us to overcome some
limitations of sample size, and to break down the effects of TDR
on baseline CD4 and pVL by drug class or amino acid position.
For example, we found that SNRTI and SNNRTI had opposing
associations with pVL; because these quantities are correlated,
their effects on pVL would have been confounded in an ‘all-or-
none’ analysis. Similarly, we have observed several compensatory
interactions among mutations that would otherwise mask the
actual effects of individual mutations on CD4 or pVL (e.g., D67N/
G and K219Q/E).
Because this study population was comprised of seroprevalent
rather than seroincident individuals , each baseline measurement
of CD4 and pVL was sampled at a point in time following an
unknown date of transmission. Consequently, there is no
guarantee that these baseline measurements were taken at a
consistent stage of infection. In other words, the CD4 count or
pVL at baseline is the result of dynamics over an unknown period
of time, starting from an unknown value upon infection. These
missing data would be required to calculate rates of change, which
would be easier to generalize to specific cases in clinical practice
where these quantities (time since infection and prognostic markers
at infection) may be known. This is a common problem of
observational cohort studies and may explain why a substantial
Figure 4. Three-dimensional scatterplot of log10-transformed
plasma viral load (pVL) as a function of Stanford scores for
NRTI and NNRTIs (SNRTI and SNNRTI). Overall, higher SNNRTI was
associated with higher pVL, while SNRTI was inversely associated with
pVL. The range of log10 pVL (1:58,6:96) was truncated to emphasize the
overall trend (omitting 73 outliers). The linear model prediction is
displayed as a wireframe surface (generated by local polynomial
regression with smoothing parameter a~0:8).
doi:10.1371/journal.pone.0021189.g004
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21189Figure 5. Box-and-whisker plots illustrating (A) the effects of SDRMs at positions D67 and K219 on CD4 cell count and (B) the
effects of SDRMs at positions M184 and K103 on plasma viral load (pVL). ‘Wildtype’ denotes sequences lacking SDRMs at both positions,
irrespective of whether any other SDRMs were present at other positions in protease or RT. Solid lines indicate the group median and open circles
denote outliers that fall outside the region defined by 1.5 times the interquartile range. Plot (A) was rescaled with respect to untransformed CD4
counts to emphasize differences among groups, trimming 4 outliers from the ‘wildtype’ group (1602, 1626, 1838, and 2073 cells/mL) from the plot
region. Sample sizes per group are annotated on each plot.
doi:10.1371/journal.pone.0021189.g005
Table 3. Coefficient estimates from AIC-selected linear models of baseline
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
and log10 plasma HIV RNA on position-specific
SDRMs and demographic and risk factors.
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
log10 plasma HIV RNA
Estimate (95% CI) P value Estimate (95% CI) P value
M41X 1.0 (0.05, 1.95) 0.04 NS
M46X NS {0:98 ({1:6, {0:35) 0.003
D67X {2:1 ({3:9, {0:4) 0:026 0.96 (0.25, 1.7) 0.009
M184X NS {1:06 ({1:44,{0:67) 1:3|10{7
L210X NS {0:6 ({1:0, {0:17) 0.007
K219X {1:2 ({2:4, {0:08) 0:037 NS
D67X:K219X 2:5 (0:14, 4:8) 0:006 {0:59 ({1:6, 0:4) 0.047
K219X:G190X {3:0 ({5:6, {0:4) 0:014 NS
L90X:M41X {1:7 ({4:4, 0:1) 0:007 NS
I54X:L210X 2:0 ({0:59, 4:7) 0:04 NS
M46X:T215X NS 1.7 (0.88, 2.5) 0.033
M184X:K103X NS 0.58 ({0.14, 1.3) 0.018
M184X:K219X NS 0.87 ({0.07, 1.8) 0.023
K219X:Y181X NS 1.43 (0.34, 2.5) 0.013
Male {0:58 ({0:9, {0:24) 7:5|10{4 NS
Sample date 23.3 (7.4, 38.9) |10{5 0:004 {20:0 ({38:4, 0:1) |10{5 0.04
Race/ethnicity
Black {0:35 ({0:61, {0:10) 0:007 {0:16 ({0:26, {0:05) 0.003
Hispanic {0:57 ({0:85, {0:29) 8:3|10{5 NS
other {0:53 ({0:98, {0:08) 0:02 NS
SDRMs are annotated by HXB2 reference residue and position (gene-specific numbering), followed by an ‘X’ to indicate a non-reference residue. Positions 46, 54, and 90
are in protease and all others are in reverse transcriptase. All estimates were averaged over an ensemble of linear models using Akaike weights. Only terms that were
statistically significant (a~0:05) are reported here. NS=not significant.
doi:10.1371/journal.pone.0021189.t003
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unaccounted for in the linear models. Furthermore, because the
baseline samples were taken either upon entry into care or prior to
initiating ARV therapy (ART), they may constitute a biased
sample of the patient population with respect to CD4 and pVL.
Recent guidelines, for example, indicate that patients should be
initiated on ART when their CD4 cell count falls below a
threshold of 500 cells per mL regardless of HIV RNA [33]
However, treatment guidelines have evolved over time [34] and
using a large sample size covering a decade of clinical practice can
ameliorate some of these biases. As guidelines have pushed
initiation of therapy to earlier time points, it could be argued that
less fit virus, with lower HIV RNA and higher CD4, would not
merit clinical significance since virtually every patient should start
therapy soon after identification; in other words, an association of
TDR with lower viral load would not result in a longer delay
between detection of HIV and the need to start therapy. However,
viral fitness and replication level may be very significant in the
prevalence of resistance mutations in the circulating virus
population, the pool of virus in a community that could potentially
be transmitted. As the pool of patients with suppressed virus
increases due to ARV treatment, the relative rates of transmitted
resistance may paradoxically increase due to a diminishing pool of
untreated wildtype virus and a greater prevalence of resistance in
the circulating virus population (10%–20% of patients who are
failing therapy [1]). In this scenario, viral fitness and its effect on
HIV RNA could determine which viruses are transmitted.
Mutations such as M184V may be transmitted less often due to
the reduced overall viral load in those subjects, whereas mutations
such as K103N may increase in prevalence. THe overall rates of
transmitted resistance would be a complex interplay between
many host and viral factors.
Some of these issues might be resolved by the analysis of
longitudinal data that are available for this study population [18].
However, this approach would create even more problems than it
could potentially address. First, we would have to accommodate
the effects of antiretroviral therapy that generally follows soon after
HIV genotyping at baseline. This is not a trivial task, not only
because it introduces a potentially large number of variables to the
analysis (one for every drug, or a minimum of three for the
predominant drug classes), but also because variation in adherence
and confounding due to variation in prescribed regimens across
clinical sites would severely complicate the interpretation of results.
Second, we would have to accommodate large amounts of missing
data due to differential follow-up among patients as well as a
sparsity of HIV sequence data relative to CD4 and pVL
measurements. In other words, HIV genotyping is performed
much less frequently. Third, it is more difficult to adjust for
confounding in longitudinal than cross-sectional data sets by
inverse probability weighting. Previous studies have successfully
employed a marginal structural modelling approach in similar but
simplified contexts [20,35]. Marginal structural models are
essentially a time-dependent generalization of the inverse proba-
bility weighting approach used here [19]. However, they are
difficult to apply in highly-structured contexts (where pVL, CD4,
drug regimen and HIV genotype all influence one another over
time) and large numbers of missing data. In sum, the analysis of
longitudinal data is a substantially different question outside the
scope of this study on the effect of TDR on pre-therapy pVL and
CD4 and must be left to future work.
Of all position-specific effects of SDRMs on baseline prognostic
markers inferred from these data, one of the largest and most
statistically significant was M184V/I. The effects of these
substitutions on the kinetics and fidelity of HIV-1 reverse
transcriptase and replication capacity in vitro are well-characterized
[36–38]. Previous studies have also documented compensatory/
epistatic interactions of other mutations acting on M184V/I,
including K219Q [11] and N384I [39]. Furthermore, Paredes and
colleagues have recently observed that in vivo fitness is reduced in
viruses carrying the M184V mutation in the absence of lamivudine
[12]. Even so, the effect of M184V/I on viral fitness in vivo is
confounded by the effects of other SDRMs and demographic/risk
factors that should be handled using a causal modeling approach
[19]. Taking such an approach, we have found that uncompen-
sated M184V/I mutations are causally associated with a 50-fold
reduction (10{1:7) in baseline pVL in therapy-naı ¨ve patients.
Table 4. Unadjusted and stabilized weight-adjusted linear models of multinomial exposure variables AM184 (M184X and (K103X or
K219X)) and AD67 (D67X and K219X) on log10 plasma HIV RNA and
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
, respectively.
Level Unadjusted model Adjusted model
Estimate (95% C.I.) P Estimate (95% C.I.) P
log10 plasma HIV RNA *AM184
AM184~04 :63 (4:58,4:67)
AM184~1 {1:10 ({1:57,{0:63) 4:4|10{6 {1:69 ({2:63,{0:74) 4:85|10{4
AM184~2 {0:236 ({0:568,0:096) 0:16 0:207 ({0:35,0:763) 0:47
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
3 p
*AD67
AD67~06 :22 (6:12,6:33)
AD67~1 {1:77 ({2:8,{0:74) 7:97|10{4 {2:14 ({2:66,{1:63) 7:5|10{16
AD67~2 {0:768 ({1:93,0:40) 0:196 0:51 (0:07,0:89) 0:016
log10 plasma HIV RNA *AD67
AD67~04 :61 (4:56,4:65)
AD67~1 0:41 (0:21,0:62) 9:0|10{5 0:40 (0:32,0:48) v2|10{16
AD67~2 {0:21 ({0:64,0:22) 0:34 0:23 (0:05,0:41) 0:011
The model intercepts are taken to be A~0 by default, i.e., none of the designated mutations are present; these estimates are unchanged in the adjusted model and are
not repeated for clarity of presentation. Significant (a~0:05) effect estimates are bolded.
doi:10.1371/journal.pone.0021189.t004
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reduction in pVL due to M184V/I [38,40,41], while M184I itself
has been estimated to reduce fitness by 23% relative to M184V
[42]. This discrepancy may be due to failing to account for
interactions with other mutations such as the compensatory
interactions with K103 and/or K219, or confounding by other
genetic and non-genetic factors affecting pVL. On the other hand,
experimental studies of M184V/I-containing recombinant HIV-1
are potentially not subject to these confounding factors, and
M184V has been reported to reduce fitness by as much as 16-fold
in vitro [11]. However, it is difficult to estimate the fitness effect of a
mutation in vivo from in vitro measures of its effect on replication
efficiency as there are other components of RT functionality that
can be affected [43].
In contrast, the clinical consequences of D67N/G and K219Q/
E are not as well known. The effects of D67N/G and K219Q/E
on CD4 in our study were mirrored by significant effects on pVL;
i.e., substitutions at D67 were causally associated with a 2.5-fold
increase in pVL that was only partially compensated by
substitutions at K219. These residues potentially form a salt
bridge and likely affect the formation of the RT 39 pocket during
polymerization [44]. Substitutions at these sites have previously
been suggested to incur a moderate fitness cost in vitro [11,45],
although these previous studies had not employed statistical
methods to separate out the effects of these substitutions from
confounding by other mutations and demographic or risk factors .
Our results give the first evidence that the transmission of D67N/
G may have deleterious virological and immunological conse-
quences in therapy-naı ¨ve patients that may be compensated by
K219Q/E.
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